AZN News and Press, AstraZeneca PLC From 04/10/24

2024-04-10 05:49:03 ET Roche ( OTCQX:RHHBY ) has obtained CE Mark for its pre-diluted VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx test.... Read the full article on Seeking Alpha For further details see: Roche companion diagnostic test wins CE Mark to i...

2024-04-09 14:53:06 ET More on STOXX Europe 600 Index: U.S. Employment Data To Set Dollar's Course Greenback Losses Extended, But Look For Consolidation In North America Rate Adjustment Underpins Greenback JPMorgan’s top European picks European...

2024-04-09 12:55:31 ET More on STOXX Europe 600 Index: U.S. Employment Data To Set Dollar's Course Greenback Losses Extended, But Look For Consolidation In North America Rate Adjustment Underpins Greenback European losers of higher financing costs - JPMorgan ...

2024-04-09 08:54:46 ET More on Vincerx Pharma Vincerx Pharma GAAP EPS of -$0.23 beats by $0.06 Seeking Alpha’s Quant Rating on Vincerx Pharma Historical earnings data for Vincerx Pharma Financial information for Vincerx Pharma Read the full a...

2024-04-06 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market’s ri...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2 expressing (IHC 3+) metastatic cancers Daiichi Sankyo (TSE: 4...

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s ENHERTU which showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers AstraZ...

2024-04-05 16:14:43 ET More on AstraZeneca, Daiichi Sankyo What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi im...

2024-04-05 07:43:40 ET More on AstraZeneca What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript FDA accepts Daiichi Sankyo-AstraZeneca...

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful ...